Technology

Otonomy

$4.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.23 (+4.89%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Otonomy and other stocks, options, and ETFs commission-free!

About OTIC

Otonomy, Inc. Common Stock, also called Otonomy, is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA. The listed name for OTIC is Otonomy, Inc. Common Stock.

CEO
David A. Weber
Employees
49
Headquarters
San Diego, California
Founded
2008
Market Cap
245.86M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
619.56K
High Today
$4.97
Low Today
$4.56
Open Price
$4.73
Volume
546.70K
52 Week High
$6.98
52 Week Low
$1.53

Collections

OTIC Earnings

-$0.48
-$0.32
-$0.16
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

PRVL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure